- Home
- DOX vs EXEL Comparison
DOX vs EXEL Comparison
Compare DOX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOX
- EXEL
- Stock Information
- Founded
- DOX 1982
- EXEL 1994
- Country
- DOX United States
- EXEL United States
- Employees
- DOX N/A
- EXEL N/A
- Industry
- DOX EDP Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOX Technology
- EXEL Health Care
- Exchange
- DOX Nasdaq
- EXEL Nasdaq
- Market Cap
- DOX 10.4B
- EXEL 11.3B
- IPO Year
- DOX 1998
- EXEL 2000
- Fundamental
- Price
- DOX $91.01
- EXEL $43.79
- Analyst Decision
- DOX Strong Buy
- EXEL Buy
- Analyst Count
- DOX 3
- EXEL 18
- Target Price
- DOX $105.33
- EXEL $42.65
- AVG Volume (30 Days)
- DOX 714.6K
- EXEL 3.5M
- Earning Date
- DOX 08-06-2025
- EXEL 08-05-2025
- Dividend Yield
- DOX 2.31%
- EXEL N/A
- EPS Growth
- DOX 6.36
- EXEL 237.58
- EPS
- DOX 4.74
- EXEL 2.20
- Revenue
- DOX $4,752,199,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- DOX N/A
- EXEL $9.37
- Revenue Next Year
- DOX $4.26
- EXEL $11.05
- P/E Ratio
- DOX $19.21
- EXEL $19.82
- Revenue Growth
- DOX N/A
- EXEL 24.49
- 52 Week Low
- DOX $77.17
- EXEL $21.82
- 52 Week High
- DOX $95.41
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- DOX 47.25
- EXEL 54.46
- Support Level
- DOX $90.36
- EXEL $39.85
- Resistance Level
- DOX $95.41
- EXEL $49.62
- Average True Range (ATR)
- DOX 1.60
- EXEL 1.50
- MACD
- DOX -0.33
- EXEL 0.06
- Stochastic Oscillator
- DOX 12.87
- EXEL 33.52
About DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.